Загрузка...
HCV Replicon Systems: Workhorses of Drug Discovery and Resistance
The development of direct-acting antivirals (DAAs) has revolutionized the state-of-the art treatment of HCV infections, with sustained virologic response rates above 90%. However, viral variants harboring substitutions referred to as resistance-associated substitutions (RASs) may be present in basel...
Сохранить в:
| Главные авторы: | , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Frontiers Media S.A.
2020-06-01
|
| Серии: | Frontiers in Cellular and Infection Microbiology |
| Предметы: | |
| Online-ссылка: | https://www.frontiersin.org/article/10.3389/fcimb.2020.00325/full |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|